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The molecular mechanisms underlying mutant p53 gain of function are becoming increasingly complex. In this issue of Cancer 
Cell, Di Agostino et al. identify the heterotrimeric transcription factor NF-Y as an interacting partner of mutant p53. They show 
that mutant p53/NF-Y complexes bind to NF-Y target promoters and recruit p300 in response to DNA damage, resulting in aber-
rant transactivation of NF-Y target genes and cell cycle deregulation. These data thereby implicate transcriptional activation 
by mutant p53 as a key mechanism responsible for its oncogenic activity.p53 is fairly unique among the family of 
tumor suppressors in that about 50% of 
all human tumors express, at relatively 
high levels, p53 protein with missense 
mutations in the DNA binding domain. 
In fact, innumerable clinical reports have 
documented mutation of virtually every 
amino acid in this ?200 amino acid 
region, with some “hot spot” mutations 
occurring at a markedly higher frequen-
cy than the others. Such p53 mutations 
can arise sporadically or are inherited 
as a germline mutation in Li-Fraumeni 
syndrome. While they usually weaken or 
abrogate sequence-specific interactions 
with DNA, the fact that these mutant 
proteins are stable and present at high 
levels in the nucleus has led to specu-
lation that they are not neutral in cells, 
but rather confer advantages for tumor 
growth. Indeed, many patients with p53 
missense mutations have an increased 
resistance to chemotherapy and poorer 
prognosis than those who have wild-type 
or no p53 protein (Soussi and Beroud, 
2001). The challenge has been to obtain 
experimental proof of, and mechanistic 
insight into, mutant p53 oncogenic gain 
of function.
There is strong experimental evi-
dence to support dominant-negative and 
gain-of-function activities of mutant p53 
(Lang et al., 2004; Olive et al., 2004). 
Mutant p53 knockin mice on two genetic 
backgrounds that either were heterozy-
gous for mutant p53 or expressed only 
mutant p53 (R172H or R270H missense 
mutations) developed tumor spectra dis-
tinct from that of p53+/− and p53−/− mice.
Two different models to explain 
mutant p53 gain of function have been 
put forward. The first proposes that 
mutant p53 regulates a specific set of 
genes that mediate its oncogenic activi-
ties. Indeed, several lines of evidence 
exist that p53 mutants not only possess 
altered target gene specificity compared 
to wild-type proteins, but also differen-
tially regulate p53 target genes (Kim and 
Deppert, 2004; Sigal and Rotter, 2000). 
Furthermore, chromatin immunopre-cancer cell 10, September 2006 © 2006 elSecipitation analyses have revealed that 
mutant forms of p53 physically associ-
ate with several promoters, for example 
MSP/MST-1 (Zalcenstein et al., 2006), 
although whether mutant p53 proteins 
bind directly to DNA or indirectly through 
other sequence-specific transcription 
factors remains less clear.
The second model proposes that 
some mutant forms of p53 acquire gain 
of function through their interactions 
with the p53 family members p63 and 
p73. The ability of mutant p53 to bind 
to and inhibit the activities of p63 and 
p73 has been shown by several groups 
(Moll et al., 2001), and taken together 
with data obtained from human tumor 
cells (Irwin et al., 2003) and the above-
mentioned mouse models (Lang et al., 
2004; Olive et al., 2004), strongly impli-
cates the inhibition of p63 or p73 as a vier inc. potential mechanism for mutant p53 
gain of function.
In this issue of Cancer Cell, Di 
Agostino et al. provide evidence for the 
first hypothesis as being responsible for 
p53 mutant gain of function following 
DNA damage (Di Agostino et al., 2006). 
The authors show that three different 
mutant p53 proteins interact with the 
heterotrimeric transcription factor NF-Y 
in vivo, and that these mutant p53/NF-Y 
complexes modulate the expression of 
key NF-Y-regulated cell cycle genes after 
adriamycin treatment. In fact, wild-type 
p53 has previously been shown to form 
a complex with NF-Y on CCAAT box-
containing promoters, and upon DNA 
damage this complex recruits histone 
deacetylases (HDACs) and releases his-
tone acetyltransferases (HATs), coincid-
ing with the repression of key cell cycle Figure 1. transcriptional activities underlying mutant p53 gain of function
a: model proposed by Di Agostino et al. (2006) in which the transcriptional regulation of nF-Y target 
genes by wild-type and mutant p53 are opposite following DnA damage due to the recruitment of 
opposing chromatin-modifying enzymes, conferring oncogenic “gain-of-function” properties to mutant 
p53 proteins.
B: Speculative model of mutant p53 gain of function, whereby the activities of a variety of transcription 
factors, such as nF-Y, ets1, Sp1, or other factors are differentially regulated by wild-type or mutant p53 
due to specific interactions with HDAcs or HAts.173
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Strikingly, Di Agostino et al. show that 
mutant p53/NF-Y complexes have the 
opposite effect on transcription to wild-
type p53/NF-Y complexes and transac-
tivate proliferative genes such as cyclin 
A, cyclin B2, cdk1, and cdc25C following 
DNA damage, resulting in activation of 
cyclin/cdk1 kinase complexes and aber-
rant cell cycle regulation.
Further, Di Agostino et al. show that 
NF-Y and mutant p53 are present at 
the promoters of NF-Y-regulated genes 
along with HDAC1 independent of DNA 
damage. Association of mutant p53 with 
these promoters, dependent on the pres-
ence of NF-Y and CCAAT box integrity, 
is increased after adriamycin treatment, 
and the p300 HAT is then recruited in a 
manner that requires mutant p53. The 
switch between HDAC1 and p300 is 
accompanied by increased acetylation 
and reduced methylation of neighboring 
histones on the cyclin B2 and cdk1 pro-
moters. In contrast, wild-type p53 inter-
acts with HDAC1 upon DNA damage to 
repress NF-Y target genes.
To gain in vivo relevance for their 
observations, Di Agostino et al. reduce 
the expression of NF-YA, a subunit of 
NF-Y, or mutant p53 using siRNA or 
shRNA, respectively. Downregulation 
of either protein impairs the induction 
of NF-Y target genes and reduces S 
phase accumulation following adria-
mycin treatment. Moreover, mutant p53 
contributes to chemoresistance of cells 
to DNA damage. Therefore, the ability 
of mutant p53 to interact with NF-Y and 
control important cell cycle regulatory 
genes defines new oncogenic gain-of-
function properties for these proteins.
It should be noted that mutant p53 
has previously been shown to switch a 
repressive transcriptional response to 
an active one. For example, wild-type 
p53 has been reported to inhibit Sp1- 
and Ets1-dependent activity, whereas 
the mutant p53 interaction enhances 
transcription mediated by these factors 
(Kim and Deppert, 2004). However, the 
mechanism behind these differential 
effects has remained speculative. The 
work of Di Agostino et al. suggests that 
specific recruitment of chromatin-modi-
fying enzymes is responsible (Figure 174 1A). Given that mutant p53 retains the 
ability to bind a similar repertoire of tran-
scription factors to wild-type p53, aber-
rant transactivation of p53 target genes 
by mutant p53 may be a widespread 
mechanism underlying mutant p53 gain 
of function (Figure 1B).
The observations made by Di Agostino 
et al. raise some interesting questions. 
First, since both wild-type and mutant 
p53 can interact with HDAC1 or p300 
in complexes containing NF-Y, how are 
HDAC1 or p300 recruited in an opposite 
fashion by wild-type or mutant p53 fol-
lowing DNA damage? Second, what is 
the function of mutant p53/NF-Y/HDAC1 
complexes under unstressed conditions? 
Further, which of the myriad of differ-
ent tumor-derived p53 mutants interact 
with and coregulate genes with NF-Y, 
and what are the structural features of 
mutant p53 and NF-Y that are neces-
sary for their physical interaction? In this 
paper the authors use both a DNA con-
tact point mutant and a conformational 
mutant to show that the gain-of-function 
activity mediated by mutant p53/NF-Y 
complexes does not depend on a spe-
cific type of p53 mutation. Nevertheless, 
it would be interesting to confirm the uni-
versality of their observations by testing a 
wider spectrum of p53 mutations. Recent 
studies have shown that various p53 
missense mutants differentially regulate 
gene expression, impacting their onco-
genicity, and in turn, tumor phenotype 
(Menendez et al., 2006). Moreover, dif-
ferent p53 mutant alleles display distinct 
tumor spectra, providing clear evidence 
that various mutants possess their own 
gain-of-function characteristics (Olive 
et al., 2004). Taken together, these data 
suggest that transcriptional complexes 
containing mutant p53 may differ depend-
ing upon the type of p53 mutation. 
Finally, given the results of Di 
Agostino et al., is the second mechanism 
whereby mutant p53 downregulates the 
proapoptotic activities of p63 and p73 
still valid? Since mutant forms of p53 are 
frequently present at significantly higher 
levels in cells than either of its siblings, 
p63 and p73 (C.P., unpublished data), 
there may well be enough mutant p53 
protein in tumor cells to perform multiple 
functions. Thus, in the absence of con-trary data, there is presently no need to 
exclude either model.
In summary, the data presented by 
Di Agostino et al. provide support for 
mutant p53 facilitating NF-Y transac-
tivation of proliferative genes as being 
a critical component of their gain of 
function in response to DNA damage. 
Additionally, they provide even more 
impetus to identify means to reactivate 
the wild-type activity and conformation 
of p53 mutant proteins, goals that will 
undoubtedly be eagerly sought in the 
future.
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